血清胱抑素C对冠心病患者预后评估的价值  

Predictive value of cystatin C for prognosis in patients with coronary heart disease

作　　者：何玉辉[1] 姚晨姣[2] 熊斌[1] 刘娟[1] 王淑燕[1] 

机构地区：[1]武警湖南总队医院内二科,长沙410006 [2]中南大学湘雅三医院内科,长沙410006

出　　处：《临床与病理杂志》2016年第10期1670-1673,共4页Journal of Clinical and Pathological Research

摘　　要：目的:探讨血清胱抑素C水平对冠心病患者预后评估中的作用。方法:选择住院且经冠脉造影等检查确诊的冠心病患者共142例,其中不稳定性心绞痛患者72例,稳定性心绞痛患者70例,并选造影正常者65例作为对照,用免疫比浊法测定血清胱抑素C浓度,对所有患者随访1年,记录主要心血管不良事件发生情况。统计分析血清胱抑素C与主要心血管不良事件的关系。结果:冠心病患者血清胱抑素C水平与主要不良心血管事件(major adverse cardiac vascular events,MACE)总事件相关,相关系数r值为0.43(P<0.05)。结论:血清胱抑素C水平可作为预测冠心病患者MACE事件的一个评价指标。Objective：To investigate the relationship between level of cystatin C and its role in evaluating patient’s prognosis. Methods：A total of 142 cases of coronary heart disease were selected for the study, among which 72 were diagnosed as unstable angina pectoris （UAP） and 70 stable angina pectoris （SAP）, and 65“healthy”people were selected as control group who were identiifed as normal by coronary angiography. Serum levels of cystatin C were measured by immunoassay. All patients were followed up for 1 year and major adverse cardiac vascular events （MACE） were recorded. Relationship between levels of cystatin C and MACE was then analyzed by statistical methods. Results：In patients with coronary heart disease serum levels of cystatin C were correlated with MACE （r=0.43, P〈0.05）. Conclusion：Cystatin C may be used as an prognostic indicator of MACE in coronary heart disease patients.

关 键 词：胱抑素C 冠心病 预后 

分 类 号：R541.4[医药卫生—心血管疾病]